MAP2K7 and breast carcinoma: These genes, combined with in-vitro proliferation assays and patient survival analysis, led to the discovery of MEK inhibitors PD19830 and BRD-K12244279, pilocarpine, and tremorine as potential new drug options for treating breast cancer.